The place of thalidomide in the treatment of multiple myeloma
Thalidomide represents the first attempt in multiple myeloma (MM) patients to overcome resistance to chemotherapy through a biological agent. The exciting results reported in the first study by Singhal et al. in 1999 [1] led to several other studies which aimed to evaluate its efficacy in different...
Saved in:
Main Authors: | Alessandro Corso (Author), Silvia Mangiacavalli (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011) -
Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011) -
Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
by: Renan Bernardes de Mello, et al.
Published: (2019) -
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017) -
In-hospital rehabilitation in the treatment of multiple myeloma
by: Alicja Mińko, et al.
Published: (2021)